28 October 2015 - The National Institute for Health and Care Excellence has published its final recommendations for paclitaxel (nanoparticle albumin bound) for pancreatic cancer, Idelalisib for chronic lymphocytic leukaemia and tolvaptan for autosomal dominant polycystic kidney disease.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-publishes-final-drug-recommendations-for-the-treatment-of-3-separate-medical-conditions